<p><strong>纽约，纽约 / ACCESS Newswire /2025 年 8 月 4 日/</strong> 如果您在 <strong>Replimune Group, Inc.</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
<p>https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5</p>
<p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
<p><strong>诉讼：</strong> 针对 Replimune Group, Inc.提起了一项集体诉讼，旨在为在 2024 年 11 月 22 日至 2025 年 7 月 21 日期间受到证券欺诈影响的股东追回损失。</p>
<p><strong>案件详情：</strong> 提起的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(1) 被告在知道或应该知道的重大问题下，鲁莽地夸大了 IGNYTE 试验的前景，导致 FDA 认为 IGNYTE 试验不充分且控制不佳；(2) 因此，被告关于 Replimune 的业务、运营和前景的陈述在所有相关时间内都是实质性虚假和误导的，或完全缺乏合理依据。</p>
<p><strong>接下来会发生什么？</strong> 如果您在相关时间段内在 Replimune Group, Inc.的股票中遭受损失——即使您仍持有股份——请访问 https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
<p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶尖证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>纽约，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>电话：(212) 363-7500</p>
<p>传真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

REPL

<p>在 Replimune Group, Inc.遭受损失的投资者被敦促在 2025 年 9 月 22 日之前联系 Levi & Korsinsky，关于一项指控证券欺诈的集体诉讼，该诉讼涉及的时间为 2024 年 11 月 22 日至 2025 年 7 月 21 日。诉讼声称该公司对 IGNYTE 试验做出了虚假陈述，导致对其商业前景产生误导性信息。Levi & Korsinsky 是一家知名的证券诉讼事务所，为受影响的股东提供无成本或无义务的帮助</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / August 4, 2025 /</strong> If you suffered a loss on your <strong>Replimune Group, Inc.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p><strong>纽约，纽约 / ACCESS Newswire /2025 年 8 月 4 日/</strong> 如果您在 <strong>Replimune Group, Inc.</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
</div><p>https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Replimune Group, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025.</p>
<div class="lb-trans"><p><strong>诉讼：</strong> 针对 Replimune Group, Inc.提起了一项集体诉讼，旨在为在 2024 年 11 月 22 日至 2025 年 7 月 21 日期间受到证券欺诈影响的股东追回损失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.</p>
<div class="lb-trans"><p><strong>案件详情：</strong> 提起的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(1) 被告在知道或应该知道的重大问题下，鲁莽地夸大了 IGNYTE 试验的前景，导致 FDA 认为 IGNYTE 试验不充分且控制不佳；(2) 因此，被告关于 Replimune 的业务、运营和前景的陈述在所有相关时间内都是实质性虚假和误导的，或完全缺乏合理依据。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Replimune Group, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下来会发生什么？</strong> 如果您在相关时间段内在 Replimune Group, Inc.的股票中遭受损失——即使您仍持有股份——请访问 https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶尖证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>纽约，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

投资者被建议在2025年9月22日之前联系 Levi & Korsinsky 以获取信息 - Replimune 集团公司 (REPL)